Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Cross-Talk between Cancer Cells and the Tumour Microenvironment: The Role of the 5-Lipoxygenase Pathway.

Moore GY, Pidgeon GP.

Int J Mol Sci. 2017 Jan 24;18(2). pii: E236. doi: 10.3390/ijms18020236. Review.

2.

Identification and Characterization of a New Protein Isoform of Human 5-Lipoxygenase.

Häfner AK, Beilstein K, Graab P, Ball AK, Saul MJ, Hofmann B, Steinhilber D.

PLoS One. 2016 Nov 17;11(11):e0166591. doi: 10.1371/journal.pone.0166591. eCollection 2016.

3.

Alox5 Blockade Eradicates JAK2V617F-Induced Polycythemia Vera in Mice.

Chen Y, Shan Y, Lu M, DeSouza N, Guo Z, Hoffman R, Liang A, Li S.

Cancer Res. 2017 Jan 1;77(1):164-174. doi: 10.1158/0008-5472.CAN-15-2933. Epub 2016 Oct 26.

PMID:
27784744
4.

Digitalization of a non-irradiated acute myeloid leukemia model.

Li R, Cheng H, Cheng T, Liu L.

BMC Syst Biol. 2016 Aug 26;10 Suppl 3:64. doi: 10.1186/s12918-016-0308-x.

5.

Chronic myeloid leukemia: reminiscences and dreams.

Mughal TI, Radich JP, Deininger MW, Apperley JF, Hughes TP, Harrison CJ, Gambacorti-Passerini C, Saglio G, Cortes J, Daley GQ.

Haematologica. 2016 May;101(5):541-58. doi: 10.3324/haematol.2015.139337. Review.

6.

Structural optimization and biological evaluation of 1,5-disubstituted pyrazole-3-carboxamines as potent inhibitors of human 5-lipoxygenase.

Zhou Y, Liu J, Zheng M, Zheng S, Jiang C, Zhou X, Zhang D, Zhao J, Ye D, Zheng M, Jiang H, Liu D, Cheng J, Liu H.

Acta Pharm Sin B. 2016 Jan;6(1):32-45. doi: 10.1016/j.apsb.2015.11.004. Epub 2016 Jan 7.

7.

Deletion of 5-Lipoxygenase in the Tumor Microenvironment Promotes Lung Cancer Progression and Metastasis through Regulating T Cell Recruitment.

Poczobutt JM, Nguyen TT, Hanson D, Li H, Sippel TR, Weiser-Evans MC, Gijon M, Murphy RC, Nemenoff RA.

J Immunol. 2016 Jan 15;196(2):891-901. doi: 10.4049/jimmunol.1501648. Epub 2015 Dec 11.

8.

β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.

Eiring AM, Khorashad JS, Anderson DJ, Yu F, Redwine HM, Mason CC, Reynolds KR, Clair PM, Gantz KC, Zhang TY, Pomicter AD, Kraft IL, Bowler AD, Johnson K, Partlin MM, O'Hare T, Deininger MW.

Leukemia. 2015 Dec;29(12):2328-37. doi: 10.1038/leu.2015.196. Epub 2015 Jul 23.

9.

The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia.

Schinnerl D, Fortschegger K, Kauer M, Marchante JR, Kofler R, Den Boer ML, Strehl S.

Blood. 2015 Feb 19;125(8):1282-91. doi: 10.1182/blood-2014-04-570960. Epub 2014 Dec 16.

10.

Potency of non-steroidal anti-inflammatory drugs in chemotherapy.

Hiľovská L, Jendželovský R, Fedoročko P.

Mol Clin Oncol. 2015 Jan;3(1):3-12. Epub 2014 Oct 16.

11.

Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia.

Lucas CM, Harris RJ, Giannoudis A, McDonald E, Clark RE.

Haematologica. 2014 Nov;99(11):1710-5. doi: 10.3324/haematol.2013.101972. Epub 2014 Sep 5.

12.

Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival.

Chen Y, Peng C, Abraham SA, Shan Y, Guo Z, Desouza N, Cheloni G, Li D, Holyoake TL, Li S.

J Clin Invest. 2014 Sep;124(9):3847-62. doi: 10.1172/JCI66129. Epub 2014 Aug 8.

13.

Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

Sato T, Goyama S, Kataoka K, Nasu R, Tsuruta-Kishino T, Kagoya Y, Nukina A, Kumagai K, Kubota N, Nakagawa M, Arai S, Yoshimi A, Honda H, Kadowaki T, Kurokawa M.

Oncogene. 2014 Oct 16;33(42):5028-38. doi: 10.1038/onc.2014.108. Epub 2014 Apr 21.

14.

Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors.

Ichim CV.

Stem Cells Transl Med. 2014 Apr;3(4):405-15. doi: 10.5966/sctm.2012-0159. Epub 2014 Mar 5. Review.

15.

Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia.

Chen Y, Li S.

Onco Targets Ther. 2014 Jan 31;7:177-86. doi: 10.2147/OTT.S41786. eCollection 2014. Review.

16.

Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistence.

Burchert A.

Curr Hematol Malig Rep. 2014 Mar;9(1):9-16. doi: 10.1007/s11899-013-0196-8. Review.

17.

Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond.

Ahmed W, Van Etten RA.

Hematology Am Soc Hematol Educ Program. 2013;2013:189-200. doi: 10.1182/asheducation-2013.1.189. Review.

18.

Molecular signatures of chronic myeloid leukemia stem cells.

Chen Y, Li S.

Biomark Res. 2013 Jun 6;1(1):21. doi: 10.1186/2050-7771-1-21.

19.

Cooperation between RUNX1-ETO9a and novel transcriptional partner KLF6 in upregulation of Alox5 in acute myeloid leukemia.

DeKelver RC, Lewin B, Lam K, Komeno Y, Yan M, Rundle C, Lo MC, Zhang DE.

PLoS Genet. 2013;9(10):e1003765. doi: 10.1371/journal.pgen.1003765. Epub 2013 Oct 10.

20.

Tgif1 regulates quiescence and self-renewal of hematopoietic stem cells.

Yan L, Womack B, Wotton D, Guo Y, Shyr Y, Davé U, Li C, Hiebert S, Brandt S, Hamid R.

Mol Cell Biol. 2013 Dec;33(24):4824-33. doi: 10.1128/MCB.01076-13. Epub 2013 Oct 7.

Supplemental Content

Support Center